argenx Schedules Call for 2024 Financial Results Review

Author: Owen Jenkins Updated: 02-20-2025 01:28 AM

Upcoming Financial Results Announcement

February 20, 2025 – argenx (Euronext & NASDAQ: ARGX) has announced a significant upcoming event. The global immunology company, dedicated to enhancing the lives of those facing severe autoimmune diseases, will host a conference call and audio webcast to discuss its financial performance and business insights.

Conference Call Details

The event is scheduled for Thursday, February 27, 2025, at 2:30 PM CET (8:30 AM ET). In this session, argenx will present its full-year financial results for 2024 and provide an update on its fourth-quarter operations.

How to Access the Webcast

Interested parties can access the live audio of the call via the Investors section of the argenx website. Following the event, a recording will be available for one year, ensuring that those unable to attend live can still catch up on the significant information shared.

Dial-In Numbers for Participants

Here are the dial-in numbers for various countries:

Belgium: 32 800 50 201
France: 33 800 943355
Netherlands: 31 20 795 1090
United Kingdom: 44 800 358 0970
United States: 1 800 715 9871
Japan: 81 3 4578 9081
Switzerland: 41 43 210 11 32

For participation, use the access code 3810049 and join the call 15 minutes early to ensure smooth entry.

About argenx

As a leader in immunotherapy, argenx focuses on addressing critical needs in the autoimmune disease landscape. Collaborating with leading academic institutions through its Immunology Innovation Program (IIP), the company transforms innovative technologies into effective antibody-based therapies.

Innovative Therapeutics

Among its key advancements, argenx developed the first globally approved neonatal Fc receptor (FcRn) blocker, used in multiple countries including the U.S., Japan, and EU regions. Their lead product, efgartigimod, is under evaluation for various serious autoimmune conditions and is part of a broader strategy involving several early-stage antibody candidates.

Ongoing Research and Development

The commitment to research and innovation remains central to argenx’s mission. With a strong focus on developing new therapies, the company aims to improve patient outcomes through advanced science and clinical trials.

Connect with argenx

For more detailed updates, visit www.argenx.com and connect through their social media platforms, including LinkedIn and Instagram.

Frequently Asked Questions

What is the purpose of the upcoming conference call?

The conference call is intended to discuss argenx's financial results for 2024 and provide updates on its business operations.

When is the conference call scheduled?

The call will take place on February 27, 2025, at 2:30 PM CET (8:30 AM ET).

How can I listen to the conference call?

Individuals can access the call through the Investors section of the argenx website.

What are some of argenx's key products?

One of the highlighted products is efgartigimod, the first approved neonatal Fc receptor blocker, undergoing evaluation for various autoimmune diseases.

How can I get in touch with argenx for inquiries?

For media inquiries, you can contact Ben Petok at bpetok@argenx.com. For investor questions, reach out to Alexandra Roy (US) at aroy@argenx.com or Lynn Elton (EU) at lelton@argenx.com.

About The Author

Hi there I'm 38-year-old author and financial consultant Owen Jenkins. Having worked in the financial sector for more than ten years, I am well-versed in the subtleties and complexity that mold our financial environment. Following a degree in finance, I worked in a number of financial institutions honing my abilities in market analysis, financial planning, and investment strategies.

My love is teaching others about investing and personal finance. My goal in writing many books and articles has been to demystify financial ideas and give readers the information they need to make wise financial decisions. I write with a direct, useful style that emphasizes doable suggestions for daily living.

Along with writing, I lead webinars and seminars where I impart knowledge on how to successfully negotiate the financial world. I also write for financial journals and show up as a guest expert on financial news programs a lot. Whether they are new to investing or want to improve their approach, my mission is to enable people to take charge of their financial futures.

Beyond work, I like to hike, play the guitar, and spend time with my family. I think that balance is crucial and want to encourage people to strike a balance between their financial aspirations and their hobbies. I want to help people succeed and achieve financial security through my work, so having a good influence.

Contact Owen Jenkins privately here. Or send an email with ATTN: Owen Jenkins as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.